Nightingale Health has created a new risk detection tool that detects whether or not a person is likely to have high levels of lipoprotein (a). If high risk is detected, the company offers a follow-up blood test to measure the value of Lp(a) to perform a diagnosis.

High levels of Lp(a) indicate an increased, genetically determined risk for cardiovascular disease. Measuring Lp(a) is a common recommendation for everyone in many guidelines; however, testing an entire population for a single blood marker is cumbersome, ineffective, and costly.

Nightingale Health’s new patent-pending risk detection tool means that only those most likely to have high Lp(a) need to undergo tests for Lp(a) itself, approximately 10-20% of a given population. The solution helps correctly find high Lp(a) individuals while saving up to 80% of costs compared with measuring entire populations.

With the latest addition, the Nightingale Health Check detects risks for heart attack, stroke, type 2 diabetes, chronic kidney disease, fatty liver disease – and now also Lp(a) – all from a single blood sample.

“This breakthrough innovation once again demonstrates Nightingale Health’s global leadership in enabling preventative healthcare. By utilizing just a single blood sample, our technology offers automated, affordable, and comprehensive risk detection that is superior to current clinical tools. The added ability to detect the risk of dangerously high levels of lipoprotein (a) further expands our capabilities in cardiovascular diseases and helps healthcare systems to detect disease risks more comprehensively and cost-efficiently than any other solution,” says Teemu Suna, Founder and CEO of Nightingale Health.